Screening for Islet Autoantibodies in the Israeli Paediatric General Population for Detection of Pre-symptomatic Type-1 Diabetes Mellitus
NCT ID: NCT04834518
Last Updated: 2024-10-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
50000 participants
OBSERVATIONAL
2021-04-01
2027-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Israeli Study for Islet Autoantibodies Screening in Families of Type-1 Diabetes Patients
NCT05788341
A National Screening Program for Islet Autoantibodies Among First-degree Relatives of T1D Patients
NCT06665815
Early Detection of Type 1 Diabetes in First Degree Relatives of Type 1 Diabetes Patients (DETECT T1D GULF)
NCT07038473
Early Detection of Type 1 Diabetes
NCT06984185
Activation Innate Immune System in Type 1 Diabetes
NCT03441919
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Negative result at the first autoantibodies screening test
Participants will be invited to repeat the screening test at the age of 2-5 years old
No interventions assigned to this group
Positive result at the first or second autoantibodies screening test
* Participants will be monitored annually for risk of type 1 diabetes. (HbA1c, repeated OGTT, monitoring of urine and blood glucose where indicated)
* Families will attend diabetes-educational program emphasizing on DKA prevention
* Stress assessment for the families involved and stress alleviating interventions when required.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Children aged 9-months- 5 years at first screening.
Exclusion Criteria
9 Months
5 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Juvenile Diabetes Research Foundation
OTHER
Rabin Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Moshe Phillip, Prof
Role: STUDY_DIRECTOR
Schneider Children's Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Soroka Medical Center
Beersheba, , Israel
Rambam Medical Center
Haifa, , Israel
Hadassah medical Center
Jerusalem, , Israel
Child Health Centers all over Israel (clalit Health Services)
Petah Tikva, , Israel
Schneider Children Medical Center of Israel
Petah Tikva, , Israel
Sheba Medical Center
Ramat Gan, , Israel
Dana-Duek children's hospital
Tel Aviv, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Eli Hershkovitz, Prof
Role: backup
Naim Shehadeh, Prof
Role: backup
David Zangen, Dr
Role: backup
Avner Cohen, Prof
Role: backup
Moshe Phillip, Prof
Role: backup
Tal Oron, Dr.
Role: backup
Orit Hamiel, Prof
Role: backup
Yael Lebenthal, Prof
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
018620RMC & 18420COM
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.